It sounds like science fiction. Follistatin gene therapy is being marketed as a once-yearly injection that builds muscle, trims fat, and reverses biological age — and a few hundred people have already paid for it.
The reality is more careful. The headline biomarker numbers are real, the trials are small, and the framing depends on who is selling the result.
Key takeaways
- Follistatin gene therapy uses DNA plasmids or an AAV vector to make your own cells produce extra follistatin, which binds and neutralizes myostatin and activin.
- Minicircle's plasmid trial in 43 healthy adults reported roughly 2 lb of lean mass, 0.87% body fat reduction, and a 7-year average epigenetic age drop at 3 months.
- Bryan Johnson paid about $25,000, was treated in Roatán in September 2023, and reported a 160% follistatin spike and 7% muscle mass increase at six months.
- The AAV1-FS344 trial in six sIBM patients (Mendell, 2017) improved the six-minute walk by 56 m/year and showed no treatment-related adverse events.
- None of these therapies are FDA-approved. Long-term safety data, especially around cancer signaling, FSH suppression, and durability, are still missing.
- Access is currently limited to clinics in Honduras, Bahamas, and Panama, or to enrolled clinical trial participants.
Follistatin gene therapy at a glance
Start with the comparison. The phrase "follistatin gene therapy" hides three very different products with different vectors, doses, regulatory status, and evidence levels.
| Approach | Vector | Setting | Best public data | Status |
|---|---|---|---|---|
| Minicircle FST-344 plasmid | Non-viral minicircle DNA, subcutaneous | GARM Bahamas / Roatán, Xtend Panama | 43-subject trial: +2 lb lean, −0.87% fat, ~7-yr epigenetic age drop, 0 serious adverse events | Not FDA-reviewed, offshore clinics only |
| Bryan Johnson protocol | Same Minicircle plasmid | Roatán, Honduras (~$25,000) | Self-reported: +160% follistatin at 2 weeks, +7% muscle mass at 6 months, 0.64 aging speed | N=1 case study, not blinded |
| AAV1-FS344 (Mendell 2017) | rAAV1 viral vector, intramuscular quadriceps | sIBM clinical trial, 6 patients | +56 m/year on 6-minute walk vs −25.8 m/year in controls (p=0.01), reduced fibrosis | Published in PMC, not approved |
| NCT07285629 klotho + follistatin | Plasmid, healthy adults | Investigational | Combination protocol, registered Dec 2025 | Registered, not yet reporting |
That table is the honest map. Everything below explains why each row reads the way it does.
How follistatin gene therapy actually works
Mechanism first. Your cells already make follistatin from the FST gene; gene therapy temporarily increases that production.
In the Minicircle approach, a single subcutaneous injection delivers a circular minicircle plasmid into fat tissue. The plasmid drifts into cell nuclei without integrating into your chromosomes, and the cells transcribe extra follistatin protein for months.
In the AAV approach used for sporadic inclusion body myositis, a recombinant adeno-associated virus serotype 1 is injected directly into the quadriceps. The viral vector delivers the FS344 isoform sequence to local muscle cells.
The downstream effect is the same. More circulating or local follistatin binds and neutralizes myostatin and activin A, which removes a brake on muscle growth and reduces some inflammation signaling.
The cost is the same too. The signal is real; the safety net is thinner than for a standard prescription drug.
The Minicircle plasmid trial
This is the most cited dataset. A 2024 preprint from Minicircle reported on 43 healthy adult volunteers who received a single subcutaneous FST-344 minicircle plasmid injection.
The reported three-month outcomes were roughly 2 lb (0.9 kg) average increase in fat-free mass, about 0.87% average reduction in body fat, about 7 years average reversal in extrinsic epigenetic age (some company materials cite 11–12 years in aged subjects), zero serious adverse events across more than 500 patients treated through partner clinics, and a mild LDL cholesterol increase of about 8 mg/dL in roughly one-third of patients.
That is a real-world signal worth noting. It is also a single-arm, unblinded, company-run dataset that has not been independently replicated. Stanford gene-therapy scientist Mark Kay has publicly questioned whether minicircle plasmids actually deliver DNA into cell nuclei in a clinically meaningful way, and no peer-reviewed third-party data confirm that they do.
Bryan Johnson's Roatán experiment
This is the story that put the topic on Joe Rogan, Peter Attia, and every longevity feed. Bryan Johnson flew to Roatán, Honduras in September 2023 for a single Minicircle FST-344 injection at a reported cost near $25,000.
His self-published six-month results were striking. He reported a 160% increase in serum follistatin two weeks post-injection, a 7% rise in muscle mass on DEXA, and a "speed of aging" score of 0.64 — meaning he claims to age about one biological year for every 19 calendar months.
Honest read on that data:
- It is a single subject without a control.
- He already had a 99th-percentile baseline and an intense protocol.
- Roatán sits in a Honduran Zone for Employment and Economic Development that operates under a different regulatory standard from the FDA.
- He paid out of pocket and was aware of the unproven status.
Fortune quoted physician-scientist Christin Glorioso warning that the therapy has "no evidence for working" and could "kill someone by inducing cancer or liver failure." That is the strongest end of the criticism — but the underlying point that long-term safety is unknown is not controversial.
The sIBM AAV trial — the cleanest evidence
This is the most rigorous public dataset on follistatin gene therapy in humans. Jerry Mendell and colleagues at Nationwide Children's enrolled six men with sporadic inclusion body myositis and injected rAAV1.CMV.huFS344 at 6 × 10¹¹ vg/kg into 12 sites in the quadriceps.
Over 1–2 years of follow-up the treated group walked 56 meters per year farther on the six-minute walk test, while untreated controls declined 25.8 meters per year (p = 0.01). Four of six treated patients showed gains between 58 and 153 meters. Biopsies at six months showed reduced fibrosis and improved fiber regeneration.
No treatment-related adverse events were reported. Anti-AAV1 and anti-follistatin antibody titers stayed at or below 1:50. FSH, LH, testosterone, and estrogen panels remained normal — important, because the FS344 isoform was chosen specifically to avoid hypothalamic-pituitary-gonadal off-target effects.
That trial is the strongest reason follistatin gene therapy is taken seriously. It is also six patients, one center, and a slowly progressing muscle disease — not healthy lifters.
The klotho + follistatin combination trial
This is the next study to watch. ClinicalTrials.gov registration NCT07285629 ("Safety and Efficacy of Klotho and Follistatin Gene Therapy") was posted in December 2025 to evaluate a combined nonviral plasmid delivery of klotho and follistatin in healthy adult volunteers.
The combination is mechanistically interesting. Klotho is a longevity-associated protein with roles in cognition and kidney function; pairing it with follistatin targets muscle plus brain plus metabolic aging in one shot. Recruitment status, sites, and dosing details remain limited at registry level.
If the combined trial reports cleanly, it will pull follistatin gene therapy one step closer to mainstream longevity protocols. If it stumbles on safety, the offshore plasmid model probably stalls with it.
Plasmid vs AAV — why the vector matters
The vectors are not equivalent. They differ on duration, immune response, off-target reach, and reversibility.
| Vector | How it works | Pros | Cons |
|---|---|---|---|
| Minicircle plasmid (Minicircle, FST-344) | Non-viral circular DNA, subcutaneous, non-integrating | No viral immune wall, can be re-dosed, effect fades in roughly a year | Weak proof that plasmid DNA actually reaches nuclei in usable amounts; no long-term human data |
| AAV1 (Mendell sIBM trial) | Engineered virus delivers FS344 sequence into muscle cells | Strongest published human evidence base; durable local expression | Pre-existing anti-AAV antibodies block many candidates; usually one shot per lifetime per serotype; immune flares possible |
| AAV9 / next-generation AAV | Wider tissue tropism, used in dystrophy programs | Could one day reach systemic muscle | Long-term safety, manufacturing cost, and immune profile still maturing |
Practical translation. Plasmid therapy is the only follistatin gene therapy a consumer can buy today, and it is also the least proven. AAV-delivered FS344 has the cleanest trial data but is not commercially available outside research settings.
Cost, access, and where it actually happens
Here is the friction picture. Real-world access is narrow and offshore.
- Minicircle partners with Global Alliance for Regenerative Medicine (GARM) in Roatán, Honduras and Paradise Island, Bahamas, and Xtend Optimal Health Center in Panama City. None operate inside US FDA jurisdiction.
- Reported pricing for Minicircle follistatin has been around $25,000 per treatment, based on Bryan Johnson's disclosure and journalist reports.
- Travel, baseline testing, and 2-year follow-up are typically required, adding several thousand dollars and several trips.
- Minimum age is 23. Treatment is not recommended for people pregnant or planning pregnancy within 12 months.
- US-based AAV follistatin therapy is currently only available inside clinical trials. There is no FDA-approved follistatin product.
Anyone evaluating this against a regular peptide route should also read the follistatin peptide overview and the where to buy follistatin guide, because the legal status and risk profile is very different.
Safety unknowns that still matter
Honest list. These are the questions a careful clinician asks before recommending follistatin gene therapy, and the company answers are not yet complete.
Does follistatin promote cancer growth? It appears protective in some cancers (breast, lung) and pro-tumorigenic in others (prostate, esophageal). Does it suppress FSH and fertility? The FS344 isoform was chosen specifically to limit this, and the sIBM trial saw no hormone shifts, but plasmid data are less detailed. Does it weaken tendons? Myostatin-deficient animal models show brittle tendons; human consequences after years of elevated follistatin are unknown. How long does the effect really last? Companies say "about a year," and independent serum follistatin data over time are limited. What happens with repeat doses? Anti-DNA or anti-follistatin antibody formation, immune flares, and dose-on-dose response are not well characterized in humans.
These are not reasons to panic. They are reasons to read the consent form carefully and not to treat a Roatán flight as a routine medical visit.
Who actually fits this
This is not a beginner intervention. A reasonable fit profile looks like:
- Adults over 35 with a clean medical workup, no cancer history, no pregnancy plans, and access to a real physician for follow-up.
- People with frailty risk or early sarcopenia who have already optimized training, protein, sleep, and resistance work and want a step further.
- People who can absorb a $25,000–$40,000 total cost including travel and accept that the long-term data are limited.
A poor fit profile looks like:
- Young lifters chasing aesthetic gains who have not used standard tools like creatine and progressive overload yet.
- People who would not be able to access proper follow-up labs after travel.
- Anyone with active or recent cancer, fertility planning, or autoimmune disease.
For the cheaper, lower-risk angle, look at the natural ways to increase follistatin guide and reduce myostatin naturally before booking a flight.
What changes first in real-world reports
This is the practical week-by-week. Self-reports from Minicircle patients and Bryan Johnson cluster around a similar pattern.
- Weeks 1–2: serum follistatin rises (Bryan Johnson reported +160% at two weeks). No visible change yet.
- Weeks 3–6: improved training recovery, fewer "junk" sore days, slightly longer pumps. Strength rather than size.
- Weeks 8–12: small but measurable lean-mass gain on DEXA, mild fat loss, some users report improved sleep and energy.
- Months 3–6: most of the body-composition signal is reported; epigenetic-age readings are usually drawn here.
- Months 9–12: serum follistatin drifts back toward baseline, and most clinics recommend reassessment.
The honest message is that month-one Instagram transformations are not the typical experience. The trial-reported lean-mass change at three months is closer to 2 lb than 20 lb.
What follistatin gene therapy is not
Set the ceiling. This is where the marketing usually outruns the evidence.
- It is not a one-shot cure for sarcopenia.
- It does not replace training, protein, sleep, or creatine.
- It is not equivalent to AAV-FS344 from the sIBM trial; that vector is not commercially available.
- It is not FDA-approved, and no insurance covers it.
- It is not the same as injecting follistatin peptide, which is reviewed in the follistatin-344 article and has its own risk profile.
If those limits feel acceptable and you can afford the friction, the data are interesting. If not, the cheaper levers still do most of the work.
Sources and notes
This article was built from DuckDuckGo and Bing SERP review, full-page competitor checks, and the underlying clinical and journalistic sources.
- Minicircle follistatin therapy page
- Plasmid delivery of follistatin gene therapy preprint (Minicircle, 43-subject trial)
- Bryan Johnson — I edited my DNA on a secret island
- MIT Technology Review on Minicircle and Próspera
- Fortune on Bryan Johnson and follistatin gene therapy
- Mendell 2017 — Follistatin gene therapy for sporadic inclusion body myositis
- NCT07285629 — Safety and Efficacy of Klotho and Follistatin Gene Therapy
- Science Advances — Follistatin gene therapy mitigates metabolic inflammation
- GARM Clinic follistatin gene therapy for longevity
Frequently Asked Questions
Is follistatin gene therapy FDA approved?
No. None of the current follistatin gene therapy products are FDA approved. Minicircle's plasmid is administered offshore in Honduras, Bahamas, and Panama, and the AAV-FS344 product is only used in clinical trials.
How much does follistatin gene therapy cost?
Reported pricing for the Minicircle plasmid approach is around $25,000 per treatment, before travel and follow-up labs. Bryan Johnson disclosed paying roughly that amount in 2023.
How long does follistatin gene therapy last?
Minicircle and partner clinics suggest effects last roughly one year, with serum follistatin drifting back to baseline by then. Independent durability data across larger groups have not been published.
What are the risks of follistatin gene therapy?
The published short-term safety profile looks mild — mostly injection-site reactions and small LDL increases. Long-term unknowns include cancer signaling, fertility effects, tendon strength, and durability with repeat dosing.
Is the Bryan Johnson follistatin protocol the same as the sIBM trial?
No. Bryan Johnson received a non-viral minicircle plasmid in a fat-tissue injection. The sIBM trial used an AAV1 viral vector injected directly into the quadriceps muscle. The mechanisms, doses, and evidence levels are different.
Can I get follistatin gene therapy in the United States?
Not as a commercial product. The only route inside the US is enrollment in an open clinical trial, such as NCT07285629 or any active AAV-follistatin study, when criteria match.
This article is for educational purposes only and is not medical advice. Gene therapies discussed here are investigational, lack FDA clearance, and carry unknown long-term risks. Talk with a qualified healthcare professional before pursuing any gene therapy, especially if you have a cancer history, fertility plans, autoimmune disease, or take regular medication.
